Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686843 | 0.86 | COMT (0.41) | COMT | |
| SCHEMBL1686711 | 0.84 | COMT (0.38) | COMTLTB4RLTB4R2 | |
| SCHEMBL9366982 | 0.84 | COMT (0.38) | COMTLTB4RLTB4R2 | |
| SCHEMBL1686996 | 0.84 | IDO1 (0.34) | — | |
| SCHEMBL6181240 | 0.84 | COMT (0.40) | COMTLTB4RLTB4R2 | |
| SCHEMBL9367369 | 0.83 | COMT (0.36) | COMT | |
| SCHEMBL9367570 | 0.82 | COMT (0.40) | COMT | |
| SCHEMBL9370311 | 0.81 | COMT (0.38) | COMTLTB4RLTB4R2 | |
| SCHEMBL9366427 | 0.80 | COMT (0.36) | COMTLTB4RLTB4R2 | |
| SCHEMBL9367581 | 0.79 | COMT (0.37) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2308874-B1 | Bridged monobactams useful as beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2484680-A1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | Basilea Pharmaceutica AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-1965798-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-0349340-B1 | Novel cephem compound, method for producing the same and anti-bacterial agent | MEIJI SEIKA CO (JP) | 1994-09-07 | — | — | EP | disclosed |
| US-4988686-A | Cephalosporin antibiotics | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1991-01-29 | — | — | US | disclosed |
| EP-0349340-A2 | Novel cephem compound, method for producing the same and anti-bacterial agent | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | COMT 386/4885AR 4605/4885LTB4R 2412/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | COMT 386/4885AR 4605/4885LTB4R 2412/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | COMT 455/4885AR 4582/4885LTB4R 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.